ARDELYX, INC. (ARDX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0396971071
ARDELYX, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 407.32 m USD |
| Gross profit | 367.78 m USD |
| Operating income | -40.98 m USD |
| EBIT | -40.53 m USD |
| Net income | -61.60 m USD |
| Diluted EPS – continuing operations | -0.26 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ARDELYX, INC.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
More stocks
- Liberty Gold Corp (LGD.TO)
- Dakota Gold Corp. (DC)
- Copper Property CTL Pass Through Trust (CPPTL)
- Jiangsu Zhenjiang New Energy Equipment Co Ltd Class A (603507.SS)
- Hengerda New Materials (Fujian) Co. Ltd. (300946.SZ)
- Carlyle Secured Lending, Inc. (CGBD)
- Surge Energy Inc (Alberta) (SGY.TO)
- WELL Health Technologies Corp (WELL.TO)
- Lectra SA (LSS.PA)
- Suzhou Shihua New Material Technology Co Ltd (688093.SS)
- Koppers Holdings Inc. (KOP)
- Sino-High (China) Co. Ltd. (301076.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.